{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:50:50Z","timestamp":1786996250163,"version":"build-2736575974"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.reuma.2011.01.001","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T15:41:13Z","timestamp":1300290073000},"page":"29-32","source":"Crossref","is-referenced-by-count":8,"special_numbering":"S3","title":["Tocilizumab en artritis reumatoide"],"prefix":"10.1016","volume":"6","author":[{"given":"Javier","family":"Rueda Gotor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Blanco Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reuma.2011.01.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/S1699-258X(09)70203-7","article-title":"La interleucina 6 en la fisiopatolog\u00eda de la artrirtis reumatoide","volume":"5","author":"Pablos \u00c1lvarez","year":"2009","journal-title":"Reumatol Clin."},{"key":"10.1016\/j.reuma.2011.01.001_bib0010","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2011.01.001_bib0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s10165-008-0125-1","volume":"19","author":"Nishimoto","year":"2009","journal-title":"Mod Rheumatol."},{"key":"10.1016\/j.reuma.2011.01.001_bib0020","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/ard.2006.068064","article-title":"Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI). Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab","volume":"66","author":"Nishimoto","year":"2007","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2011.01.001_bib0025","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet."},{"issue":"Suppl2","key":"10.1016\/j.reuma.2011.01.001_bib0030","first-page":"L11","article-title":"Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to methotrexate: The LITHE study","volume":"589","author":"Kremer","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2011.01.001_bib0035","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reuma.2011.01.001_bib0040","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2011.01.001_bib0045","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 10","key":"10.1016\/j.reuma.2011.01.001_bib0050","first-page":"412","article-title":"Interim Results of the TAMARA Study Effectiveness and Safety of the Interleukin-6 (IL-6) Receptor Antagonist Tocilizumab After 4 and 24 Weeks in Patients with Active Rheumatoid Arthritis (RA) [abstract]","volume":"60","author":"Rubbert-Roth","year":"2009","journal-title":"Arthritis Rheum."},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2011.01.001_bib0055","first-page":"379","article-title":"Tocilizumab in patients with rheumatoid arthritis and an inadequate response to dmards and\/or tnf inhibitor therapy: ACT-SURE preliminary results","volume":"69","author":"Bykerk","year":"2010","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2011.01.001_bib0060","first-page":"386","article-title":"Efficacy of tocilizumab in patients with ra and inadequate response to DMARDs or TNF inhibitors: up to 3.5-year data from ongoing extension studies","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 3","key":"10.1016\/j.reuma.2011.01.001_bib0065","first-page":"386","article-title":"Efficacy of Tocilizumab in patients with rheumatoid arthritis who had never been exposed to or had never failed methotrexate: analysis of up to 3 years of treatment in a long-term extension study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reuma.2011.01.001_bib0070","first-page":"1669","article-title":"Safety of tocilizumab in patients with rheumatoid arthritis: Pooled analysis of five phase 3 clinical trials","volume":"589 Suppl","author":"Smolen","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"Suppl3","key":"10.1016\/j.reuma.2011.01.001_bib0075","first-page":"544","article-title":"Safety of tocilizumab in patients with rheumatoid arthritis: analysis of median of 2.6 years of treatment in long-term extension studies","volume":"69","author":"Van Vollenhoven","year":"2010","journal-title":"Ann Rheum Dis."}],"container-title":["Reumatolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X11000210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1699258X11000210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T19:23:20Z","timestamp":1543865000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1699258X11000210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":15,"alternative-id":["S1699258X11000210"],"URL":"https:\/\/doi.org\/10.1016\/j.reuma.2011.01.001","relation":{},"ISSN":["1699-258X"],"issn-type":[{"value":"1699-258X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}